Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

被引：3
|
作者：
Zhou, C. [1 ]
Cheng, Y. [2 ]
He, Y. [3 ]
Li, W. [4 ]
Zhang, H. [5 ]
Zhou, Q. [6 ,7 ]
Wang, B. [8 ]
Liu, C. [9 ]
Ramalingam, S. [10 ]
Walding, A. [11 ]
Saggese, M. [11 ]
Wang, J. [12 ]
Fan, M. [12 ]
Wu, Y. [6 ,7 ]
机构：
[1] Tongji Univ, Pulm Hosp, Shanghai, Peoples R China
[2] Jilin Prov Canc Hosp, Thorac Oncol, Changchun, Jilin, Peoples R China
[3] Daping Hosp, Resp Dis, Chongqing, Peoples R China
[4] Jinlin Univ, Hosp 1, Changchun, Jilin, Peoples R China
[5] Forth Mil Med Univ, Tangdu Hosp, Oncol, Xian, Shaanxi, Peoples R China
[6] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[7] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[8] Yangzhou Univ, Subei PeopleS Hosp, Dept Oncol, Yangzhou, Jiangsu, Peoples R China
[9] Xinjiang Med Univ, Tumor Hosp, Urumqi, Peoples R China
[10] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
[11] Astrazeneca, Global Med Dev, Cambridge, England
[12] Astrazeneca, Global Med Dev, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
osimertinib; China; NSCLC;
D O I：
10.1016/j.jtho.2018.08.669
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-112
引用
收藏
页码：S507 / S508
页数：2
相关论文
共 50 条
  • [31] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
    Ricciuti, Biagio
    Chiari, Rita
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
  • [32] Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)
    Janne, P.
    Planchard, D.
    Cheng, Y.
    Yang, J. C. -H.
    Yanagitani, N.
    Kim, S. -W.
    Sugawara, S.
    Yu, Y.
    Fan, Y.
    Geater, S. L.
    Laktionov, K.
    Lee, C. K.
    Valdivieso, N.
    Ahmed, S.
    Maurel, J. -M.
    Andrasina, I.
    Goldman, J.
    Ghiorghiu, D.
    Kulkarni, D.
    Huang, X.
    Kobayashi, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S36 - S37
  • [33] Osimertinib With/Without Platinum-Based Chemotherapy as First-Line Treatment in Patients With EGFRm Advanced NSCLC (FLAURA2)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 3 - 4
  • [34] Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism
    He, Y.
    Zhao, C.
    Li, X.
    Ren, S.
    Jiang, T.
    Zhang, J.
    Su, C.
    Chen, X.
    Cai, W.
    Gao, G.
    Li, W.
    Wu, F.
    Li, J.
    Zhao, J.
    Zhou, F.
    Hu, Q.
    Hirsch, F. R.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1970 - S1970
  • [35] The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI
    Lu, S.
    Wang, Q.
    Zhang, G.
    Dong, X.
    Yang, C.
    Song, Y.
    Chang, G.
    Lu, Y.
    Pan, H.
    Chiu, C.
    Wang, Z.
    Feng, J.
    Zhou, J.
    Xu, X.
    Guo, R.
    Chen, J.
    Yang, H.
    Chen, Y.
    Yu, Z.
    Shiah, H.
    Wang, C.
    Yang, N.
    Fang, J.
    Wang, P.
    Wang, K.
    Hu, Y.
    He, J.
    Wang, Z.
    Shi, J.
    Chen, S.
    Cheng, Y.
    Su, W.
    Hsia, T.
    Cui, J.
    Sun, Y.
    Yang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S208 - S209
  • [36] First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Wu, Qiang
    Luo, Wuxia
    Li, Wen
    Wang, Ting
    Huang, Lin
    Xu, Feng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Lim, Sun Min
    Lee, Jii Bum
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 376 - 379
  • [38] Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Chen, Lanyi Nora
    Lee, Alexandria T. M.
    Nagasaka, Misako
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 380 - 384
  • [39] First-line concomitant EGFR-TKI plus chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials
    Landre, Thierry
    Assie, Jean-Baptiste
    Chouahnia, Kader
    Des Guetz, Gaetan
    Auliac, Jean-Bernard
    Chouaid, Christos
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (08) : 775 - 780
  • [40] Real-world molecular testing, treatment patterns and clinical outcomes in Chinese advanced NSCLC patients, who have progressed on first-line EGFR-TKI therapy (PISCES)
    Tian, P.
    Wu, L.
    Zhou, C.
    Tan, J.
    Wang, K.
    Luo, F.
    Liu, Y.
    Guo, Y.
    Li, Y.
    Liu, Z.
    Gong, Y.
    Wang, Y.
    Li, W.
    ANNALS OF ONCOLOGY, 2023, 34
12345